Shanghai Jizhi Biochemical Technology Co., Ltd
China
Product Name: Ritonavir
Price: ￥648.0/10mg ￥2658.0/50mg
Purity: 98.0%
Stocking Period: 2 Day
Contact: Liu jia

DC Chemicals Limited
China
Product Name: Ritonavir
Price: $150.0/100mg $300.0/250mg $600.0/1g
Purity: 98.0%
Stocking Period: 3 Day
Contact: Tony Cao

Henan Tianfu Chemical Co., Ltd.
China
Product Name: Ritonavir
Price: $Inquiry/1kg $Inquiry/25kg $Inquiry/1000kg $Inquiry/10ton
Purity: 99.0%
Stocking Period: Inquiry
Contact: Anson

155213-67-5

155213-67-5 structure

155213-67-5 structure

Name: Ritonavir
Chemical Name: ritonavir
CAS Number: 155213-67-5
Molecular Formula: C₃₇H₄₈N₆O₅S₂
Molecular Weight: 720.944
Catalog: API Synthetic anti-infective drugs Antiviral drugs
Create Date: 2018-05-28 08:00:00
Modify Date: 2024-01-02 09:43:43
Ritonavir is an inhibitor of HIV protease used to treat HIV infection and AIDS.

Name	ritonavir
Synonyms	[5S-(5R,8R,10R,11R)]-10-Hydroxy-2-methyl-5-(1-methylethyl)-1-[2-(1-methylethyl)-4-thiazolyl]-3,6-dioxo-8,11-bis(phenylmethyl)-2,4,7,12-tetraazatridecan-13-oic acid 5-thiazolylmethyl ester Norvir Ritonavir EINECS 208-127-9 N-[(2S,4S,5S)-4-Hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N-{[(2-isopropyl-1,3-thiazol-4-yl)methyl](methyl)carbamoyl}-L-valinamide Ritonavi Carbamic acid, N-[(1S,2S,4S)-2-hydroxy-4-[[(2S)-3-methyl-2-[[[methyl[[2-(1-methylethyl)-4-thiazolyl]methyl]amino]carbonyl]amino]-1-oxobutyl]amino]-5-phenyl-1-(phenylmethyl)pentyl]-, 5-thiazolylmethyl ester ABT-538 (1E,2S)-N-[(2S,4S,5S)-4-Hydroxy-5-{(E)-[hydroxy(1,3-thiazol-5-ylmethoxy)methylene]amino}-1,6-diphenyl-2-hexanyl]-2-[(E)-(hydroxy{[(2-isopropyl-1,3-thiazol-4-yl)methyl](methyl)amino}methylene)amino]-3-methylbutanimidic acid 1,3-Thiazol-5-ylmethyl-[(1S,2S,4S)-1-benzyl-2-hydroxy-4-({(2S)-3-methyl-2-[(methyl{[2-(1-methylethyl)-1,3-thiazol-4-yl]methyl}carbamoyl)amino]butanoyl}amino)-5-phenylpentyl]carbamat N-[(1S,3S,4S)-1-benzyl-3-hydroxy-5-phenyl-4-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}pentyl]-N-(methyl{[2-(1-methylethyl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide [(1S,2S,4S)-1-benzyl-2-hydroxy-4-({(2S)-3-méthyl-2-[(méthyl{[2-(1-méthyléthyl)-1,3-thiazol-4-yl]méthyl}carbamoyl)amino]butanoyl}amino)-5-phénylpentyl]carbamate de 1,3-thiazol-5-ylméthyle Butanimidic acid, N-[(1S,3S,4S)-3-hydroxy-4-[[(1E)-hydroxy(5-thiazolylmethoxy)methylene]amino]-5-phenyl-1-(phenylmethyl)pentyl]-2-[[(1E)-hydroxy[methyl[[2-(1-methylethyl)-4-thiazolyl]methyl]amino]methylene]amino]-3-methyl-, (1E,2S)- N-[(2S,4S,5S)-4-Hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}-2-hexanyl]-N-{[(2-isopropyl-1,3-thiazol-4-yl)methyl](methyl)carbamoyl}-L-valinamide carbamic acid, [(1S,2S,4S)-2-hydroxy-4-[[(2S)-3-methyl-2-[[[methyl[[2-(1-methylethyl)-4-thiazolyl]methyl]amino]carbonyl]amino]-1-oxobutyl]amino]-5-phenyl-1-(phenylmethyl)pentyl]-, 5-thiazolylmethyl es N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N2-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide Liponavir Core 1,3-thiazol-5-ylmethyl [(1S,2S,4S)-1-benzyl-2-hydroxy-4-({(2S)-3-methyl-2-[(methyl{[2-(1-methylethyl)-1,3-thiazol-4-yl]methyl}carbamoyl)amino]butanoyl}amino)-5-phenylpentyl]carbamate A-84538 ABT-538 Abbott 84538 Norvi (2S,3S,5S)-5-[N-[N-[[N-methyl-N-[(2-isopropyl-4-thiazolyl)methyl]amino]carbonyl]valinyl]amino]-2-[N-[(5-thiazolyl)methoxycarbonyl]amino]-1,6-diphenyl-3-hydroxyhexane RITONA MFCD04115732 carbamic acid, [(1S,2S,4S)-2-hydroxy-4-[[(2S)-3-methyl-2-[[[methyl[[2-(1-methylethyl)-4-thiazolyl]methyl]amino]carbonyl]amino]-1-oxobutyl]amino]-5-phenyl-1-(phenylmethyl)pentyl]-, 5-thiazolylmethyl ester

Description	Ritonavir is an inhibitor of HIV protease used to treat HIV infection and AIDS.
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> HIV Protease Signaling Pathways >> Anti-infection >> HIV Research Areas >> Infection
In Vitro	Ritonavir is an inhibitor of CYP3A4 mediated testosterone 6β-hydroxylation with mean Ki of 19 nM and also inhibits tolbutamide hydroxylation with IC50 of 4.2 μM[1]. Ritonavir is found to be a potent inhibitor of CYP3A-mediated biotransformations (nifedipine oxidation with IC50 of 0.07 mM, 17alpha-ethynylestradiol 2-hydroxylation with IC50 of 2 mM; terfenadine hydroxylation with IC50 of 0.14 mM). Ritonavir is also an inhibitor of the reactions mediated by CYP2D6 (IC50=2.5 mM) and CYP2C9/10 (IC50=8.0 mM)[2]. Ritonavir results in an increase in cell viability in uninfected human PBMC cultures. Ritonavir markedly decreases the susceptibility of PBMCs to apoptosis correlated with lower levels of caspase-1 expression, decreases in annexin V staining, and reduces caspase-3 activity in uninfected human PBMC cultures. Ritonavir inhibits induction of tumor necrosis factor (TNF) production by PBMCs and monocytes in a time- and dose-dependent manner at nontoxic concentrations[3]. Ritonavir inhibits p-glycoprotein-mediated extrusion of saquinavir with an IC50 of 0.2 μM, indicating a high affinity of ritonavir for p-glycoprotein[4]. Ritonavir inhibits human liver microsomal metabolism of ABT-378 potently with Ki of 13 nM. Ritonavir combined with ABT-378 (at 3:1 and 29:1 ratios) inhibits CYP3A (IC50=1.1 and 4.6 μM), albeit less potently than Ritonavir (IC50=0.14 μM)[5].
References	[1]. Eagling VA, et al. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol. 1997 Aug;44(2):190-4. [2]. Kumar GN, et al. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther. 1996 Apr;277(1):423-31. [3]. Weichold FF, et al. HIV-1 protease inhibitor ritonavir modulates susceptibility to apoptosis of uninfected T cells. J Hum Virol. 1999 Sep-Oct;2(5):261-9. [4]. Drewe J, et al. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem Pharmacol. 1999 May 15;57(10):1147-52. [5]. Kumar GN, et al. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction. Drug Metab Dispos. 1999 Aug;27(8):902-8.

Density	1.2±0.1 g/cm3
Boiling Point	947.0±65.0 °C at 760 mmHg
Melting Point	120-122°C
Molecular Formula	C₃₇H₄₈N₆O₅S₂
Molecular Weight	720.944
Flash Point	526.6±34.3 °C
Exact Mass	720.312744
PSA	202.26000
LogP	5.28
Vapour Pressure	0.0±0.3 mmHg at 25°C
Index of Refraction	1.600
Storage condition	-20°C Freezer

Symbol	GHS07
Signal Word	Warning
Hazard Statements	H302 + H312 + H332
Precautionary Statements	P261-P280-P301 + P312 + P330
Hazard Codes	Xi
Risk Phrases	R36/38:Irritating to eyes and skin .
Safety Phrases	26-37/39
RIDADR	NONH for all modes of transport
RTECS	XA5310000
HS Code	2942000000

224631-15-6 structure

224631-15-6

144164-11-4 structure

144164-11-4

~%

155213-67-5 structure

155213-67-5

Literature: WO2006/90264 A1, ; Page/Page column 23-24 ;

6306-52-1 structure

6306-52-1

~%

155213-67-5 structure

155213-67-5

Literature: Journal of Medicinal Chemistry, , vol. 41, # 4 p. 602 - 617

144163-97-3 structure

144163-97-3

~%

155213-67-5 structure

155213-67-5

Literature: Journal of Medicinal Chemistry, , vol. 41, # 4 p. 602 - 617

154212-60-9 structure

154212-60-9

~%

155213-67-5 structure

155213-67-5

Literature: Journal of Medicinal Chemistry, , vol. 41, # 4 p. 602 - 617

162537-10-2 structure

162537-10-2

~%

155213-67-5 structure

155213-67-5

Literature: Journal of Medicinal Chemistry, , vol. 41, # 4 p. 602 - 617

154248-99-4 structure

154248-99-4

~%

155213-67-5 structure

155213-67-5

Literature: Journal of Medicinal Chemistry, , vol. 41, # 4 p. 602 - 617

154212-61-0 structure

154212-61-0

144164-11-4 structure

144164-11-4

~%

155213-67-5 structure

155213-67-5

Literature: Journal of Medicinal Chemistry, , vol. 41, # 4 p. 602 - 617

Precursor 8
224631-15-6 144164-11-4 6306-52-1 144163-97-3
154212-60-9 162537-10-2 154248-99-4 154212-61-0
DownStream 0

HS Code	2942000000